First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7 (PTK7), in Advanced Solid Tumors

CONCLUSIONS: This PTK7-targeted ADC demonstrated therapeutic activity in previously treated patients with OvCa, NSCLC, and TNBC at a dose range of 2.1-3.2 mg/kg, supporting further clinical evaluation to refine dose, schedule, and predictive tissue biomarker testing in patients with advanced malignancies.PMID:34083232 | DOI:10.1158/1078-0432.CCR-20-3757

Source: Clinical Genitourinary Cancer - June 4, 2021 Category: Cancer & Oncology Authors: Michael L Maitland Jasgit C Sachdev Manish R Sharma Victor Moreno Valentina Boni Shivaani Kummar Erica Stringer-Reasor Nehal Lakhani Allison R Moreau Dawei Xuan Ruifeng Li Eric L Powell Amy Jackson-Fisher Michelle Bowers Shilpa Alekar Xiaohua Xin Anthony Source Type: research